High Intensity Statins in Acute Coronary Syndrome Part II: A comparison of Atorvastatin and Rosuvastatin for use in ACS, Clinical trials in India and Place for statins in current guidelines
Article Sidebar
Main Article Content
Abstract
The role of high-intensity statins in the management of Acute Coronary Syndrome (ACS) has been a focal point of cardiovascular research, with a particular emphasis on comparing the efficacy and safety of Atorvastatin (ATV) and Rosuvastatin (RSV) in mitigating cardiovascular risk.
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
All open access articles published in the journal are distributed under the terms of the CC-BY-NC-SA 4.0 license (Creative Commons Attribution-Non-commercial-ShareAlike 4.0 International License) which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original work is properly cited and distributed under the same license (ShareAlike). Under Creative Commons, authors retain copyright in their articles.
References
Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study). Am J Cardiol. 2012 May;109(9):1239–46.
Hall AS, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, Copeland J, et al. A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention & Rehabilitation. 2009 Dec;16(6):712–21.
Bailey KM, Romaine SPR, Jackson BM, Farrin AJ, Efthymiou M, Barth JH, et al. Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction. Circ Cardiovasc Genet. 2010 Jun;3(3):276–85.
Lablanche JM, Danchin N, Farnier M, Tedgui A, Vicaut E, Alonso J, et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008 Jun;101(6):399–406.
Lablanche JM, Leone A, Merkely B, Morais J, Alonso J, Santini M, et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: Results of the CENTAURUS study. Arch Cardiovasc Dis. 2010 Mar;103(3):160–9.
Shah CP, Shah BP, Dani SI, Channa BB, Lakshmanan SS, Krishnamani NC, et al. Efficacy and safety of the intensive dose of rosuvastatin 40 mg/day in patients with acute coronary syndrome and at high risk of cardiovascular disease-ROSUVEES-2. Indian Heart J. 2016 Nov;68(6):766–71.
Kumar B, Shah MAA, Kumar R, Kumar J, Memon A. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome. Cureus. 2019 Jun 14;
Umrani S, Jamshed W, Rizwan A. Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Markers in Acute Coronary Syndrome. Cureus. 2020 Nov 28;
Rahhal A, Khir F, Orabi B, Chbib S, Al-Khalaila O, Abdelghani MS, et al. A Comparative Study of High-intensity Rosuvastatin Versus Atorvastatin Therapy Post-acute Coronary Syndrome Using Real-world Data. Curr Probl Cardiol. 2022 Jul;47(7):100956.
Takagi H, Umemoto T. A Meta-Analysis of Randomized Head-to-Head Trials for Effects of Rosuvastatin Versus Atorvastatin on Apolipoprotein Profiles. Am J Cardiol. 2014 Jan;113(2):292–301.
Toyama K, Sugiyama S, Oka H, Iwasaki Y, Sumida H, Tanaka T, et al. Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease. Atherosclerosis. 2011 Jul;217(1):158–64.
McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract. 2010 May 12;64(8):1052–61.
Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, et al. Treating to target patients with primary hyperlipidaemia:comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006 Jun 11;22(6):1123–31.
Berne C, Siewert-Delle A. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005 Dec 3;4(1):7.
JONES P, HUNNINGHAKE D, FERDINAND K, STEIN E, GOLD A, CAPLAN R, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004 Sep;26(9):1388–99.
Stein EA, Strutt K, Southworth H, Diggle PJ, Miller E. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003 Dec;92(11):1287–93.
Lloret R, Yčas J, Stein M, Haffner S. Comparison of Rosuvastatin Versus Atorvastatin in Hispanic-Americans With Hypercholesterolemia (from the STARSHIP Trial). Am J Cardiol. 2006 Sep;98(6):768–73.
Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004 Jul;148(1):105.
Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol. 2003 Jan;91(1):33–41.
Rosenson RS, Otvos JD, Hsia J. Effects of Rosuvastatin and Atorvastatin on LDL and HDL Particle Concentrations in Patients With Metabolic Syndrome. Diabetes Care. 2009 Jun 1;32(6):1087–91.
Wouter Jukema J, Liem AH, Dunselman PHJM, van der Sloot JAP, Lok DJA, Zwinderman AH. LDL‐C/HDL‐C ratio in subjects with cardiovascular disease and a low HDL‐C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005 Nov 17;21(11):1865–74.
Clearfield MB, Amerena J, Bassand JP, García HRH, Miller SS, Sosef FF, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006 Dec 21;7(1):35.
Leiter LA, Rosenson RS, Stein E, Reckless JPD, Schulte KL, Schleman M, et al. Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis. 2007 Oct;194(2):e154–64.
Park JS, Kim YJ, Choi JY, Kim YN, Hong TJ, Kim DS, et al. Comparative Study of Low Doses of Rosuvastatin and Atorvastatin on Lipid and Glycemic Control in Patients with Metabolic Syndrome and Hypercholesterolemia. Korean J Intern Med. 2010;25(1):27.
Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, et al. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002 Dec;144(6):1044–51.
Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001 Sep;88(5):504–8.
Ballantyne CM, Bertolami M, Garcia HRH, Nul D, Stein EA, Theroux P, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May;151(5):975.e1-975.e9.
Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int J Cardiol. 2005 Apr;100(2):309–16.
Deedwania PC, Gupta M, Stein M, Yčas J, Gold A. Comparison of Rosuvastatin Versus Atorvastatin in South-Asian Patients at Risk of Coronary Heart Disease (from the IRIS Trial). Am J Cardiol. 2007 Jun;99(11):1538–43.
Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, et al. Efficacy and Tolerability of Rosuvastatin and Atorvastatin when Force-Titrated in Patients with Primary Hypercholesterolemia. Cardiology. 2008;111(4):219–28.
Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, et al. Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. J Cardiovasc Pharmacol Ther. 2010 Jun 10;15(2):167–74.
WOLFFENBUTTEL BHR, FRANKEN AAM, VINCENT HH. Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Intern Med. 2005 Jun 23;257(6):531–9.
Stalenhoef AFH, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study†. Eur Heart J. 2005 Dec 1;26(24):2664–72.
Rader DJ, Davidson MH, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am J Cardiol. 2003 Mar;91(5):20–3.
Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol. 2003 Mar;91(5):3–10.
Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, et al. Comparison of Efficacy and Safety of Rosuvastatin Versus Atorvastatin in African-American Patients in a Six-Week Trial. Am J Cardiol. 2006 Jan;97(2):229–35.
Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabetic Medicine. 2007 May 22;24(5):541–9.
Joshi SR, Anjana RM, Deepa M, Pradeepa R, Bhansali A, Dhandania VK, et al. Prevalence of Dyslipidemia in Urban and Rural India: The ICMR–INDIAB Study. PLoS One. 2014 May 9;9(5):e96808.
Shah CP, Kumbla DK, Moorthy A, Murthy S, Aneja P, Gotur J, et al. A post-marketing study evaluating the lipid-altering efficacy and safety of approved dose ranges of rosuvastatin in Indian hyperlipidemia patients in routine clinical practice (ROSUVEES). Journal of Indian College of Cardiology. 2015 Dec;5(4):282–90.
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and Niacin, Antioxidant Vitamins, or the Combination for the Prevention of Coronary Disease. New England Journal of Medicine. 2001 Nov 29;345(22):1583–92.
MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). The Lancet. 1994 Sep;344(8923):633–8.
Mitchell LB, Powell JL, Gillis AM, Kehl V, Hallstrom AP. Are lipid-lowering drugs also antiarrhythmic drugs? J Am Coll Cardiol. 2003 Jul;42(1):81–7.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation. 2014 Dec;130(25):2354–94.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Circulation. 2014 Jun 24;129(25_suppl_2)